Form 4: Y-mAbs Therapeutics CFO Bo Kruse Sells Shares After Exercising Stock Options

Bo Kruse, EVP, CFO, Secretary & Treasurer of Y-mAbs Therapeutics, Inc., executed transactions involving the exercise of stock options and subsequent sale of common stock on May 30 and 31, 2024.

Summary

• Bo Kruse, the EVP, CFO, Secretary & Treasurer of Y-mAbs Therapeutics, Inc., engaged in transactions involving the company's stock.
• On May 30, 2024, Kruse exercised options to acquire 28,629 shares of common stock at a price of $2 per share and then sold the same amount of shares at a weighted average price of $12.03 per share.
• On May 31, 2024, Kruse exercised options to acquire 31,371 shares of common stock at a price of $2 per share and then sold the same amount of shares at a weighted average price of $12.07 per share.
• Following these transactions, Kruse directly owns 210,877 shares of Y-mAbs Therapeutics, Inc.
• All stock options exercised were vested.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment, but the sale of shares could be interpreted neutrally or slightly negatively depending on the context.

Industry Context

Executive stock option exercises and sales are common in the pharmaceutical industry as part of compensation packages. Monitoring these transactions can provide insights into executive sentiment and potential future stock performance.

Stakeholder Impact

• Shareholders may be interested in the transactions of company executives as indicators of company performance and executive confidence.
• The transactions have a short term impact on the float of the stock.

Key Dates